Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $81.43

MoonLake Immunotherapeutics (NASDAQ:MLTXGet Free Report) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $81.43.

A number of equities analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $73.00 price objective (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of MoonLake Immunotherapeutics in a report on Monday, September 23rd. Finally, HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Friday, January 10th.

Get Our Latest Analysis on MLTX

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several institutional investors have recently bought and sold shares of the stock. US Bancorp DE purchased a new position in MoonLake Immunotherapeutics during the 3rd quarter worth $44,000. Quarry LP lifted its position in shares of MoonLake Immunotherapeutics by 172.7% during the second quarter. Quarry LP now owns 3,000 shares of the company’s stock valued at $132,000 after purchasing an additional 1,900 shares in the last quarter. Barclays PLC boosted its holdings in MoonLake Immunotherapeutics by 1,269.2% during the third quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after purchasing an additional 5,229 shares during the last quarter. Handelsbanken Fonder AB grew its position in MoonLake Immunotherapeutics by 26.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock worth $655,000 after purchasing an additional 2,700 shares in the last quarter. Finally, AlphaCentric Advisors LLC purchased a new stake in MoonLake Immunotherapeutics in the 3rd quarter valued at about $706,000. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Stock Performance

Shares of MLTX stock opened at $46.50 on Friday. MoonLake Immunotherapeutics has a fifty-two week low of $37.55 and a fifty-two week high of $64.98. The stock has a 50 day simple moving average of $52.13 and a two-hundred day simple moving average of $49.02. The company has a market cap of $2.97 billion, a P/E ratio of -36.05 and a beta of 1.31.

MoonLake Immunotherapeutics (NASDAQ:MLTXGet Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). During the same quarter in the prior year, the business posted ($0.18) EPS. On average, research analysts predict that MoonLake Immunotherapeutics will post -1.75 earnings per share for the current year.

About MoonLake Immunotherapeutics

(Get Free Report

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Featured Stories

Analyst Recommendations for MoonLake Immunotherapeutics (NASDAQ:MLTX)

Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.